cis-2-methyl-5-[2-(pyridin-3-yl)ethenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole | 1061352-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: cis-2-methyl-5-[2-(pyridin-3-yl)ethenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
• 英文别名: (Z)-2-methyl-5-(2-(pyridin-3-yl)vinyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole；cis-2-methyl-5-[2-(pyridin-3-yl)vinyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole；3-[(1Z)-2-{2-Methyl-1H,2H,3H,4H,5H-pyrido[4,3-B]indol-5-YL}ethenyl]pyridine；2-methyl-5-[(Z)-2-pyridin-3-ylethenyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
• CAS: 1061352-30-4
• 化学式: C₁₉H₁₉N₃
• 分子量: 289.38
• InChiKey: UHCVDZYZONGEEX-WQLSENKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-乙炔基吡啶 、 2-甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚 在 四正丁基硫酸铵 、 potassium hydroxide 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 6.0h， 以75%的产率得到cis-2-methyl-5-[2-(pyridin-3-yl)ethenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
  参考文献：
  名称：

  作为 5-HT6 和 H1 受体拮抗剂的新型 5,8-二取代-2-甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b] 吲哚的合成和生物学评价

  摘要：

  描述了 Dimebon 的一系列新型 γ-咔啉类似物的合成、生物学评价和构效关系 (SAR)。在研究的化合物中，四氢-γ-咔啉 5b（2,8-二甲基-5-[cis-2-pyridin-3-ylvinyl]-2,3,4,5-四氢咔啉）已被鉴定为最有效的小分子拮抗剂，特别是针对组胺 H1 和血清素 5-HT6 受体（IC50 < 0.45 μM 和 IC50 = 0.73 μM，分别）。对测试化合物进行的全面比较 SAR 研究揭示了侧取代基的性质与相关拮抗活性之间的显着相关性。

  DOI：

  10.1002/ardp.200900056

文献信息

• SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
  申请人：Ivachtchenko Alexandre Vasilievich

  公开号：US20190233409A1

  公开（公告）日：2019-08-01

  The present invention relates to compound of the formula 1.2, or a pharmaceutically acceptable salt, or hydrate thereof wherein R 1 is C 1 -C 5 alkyl; R 2 , is independently hydrogen, halogen, C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2,3, or 4; Ar is unsubstituted phenyl or substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, a substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle one or, with two nitrogen atoms in the heterocycle; excluding the compounds of the formulas A1-A4 The invention relates to the novel chemical compounds, methods for their preparation and use as antagonists of 5-HT 6 receptors, simultaneously regulating homeostasis of calcium ions in cells. The invention relates to the novel annelated azaheterocycles—2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, to methods for their preparation, to pharmaceutical compositions, including these compounds as active substances, and to methods of treatment and profylaxis of various diseases.

  本发明涉及公式1.2的化合物，或其药学上可接受的盐或水合物，其中R1为C1-C5烷基；R2独立地为氢、卤素、C1-C3烷基、CF3、OCF3或OCH3；i为1、2、3或4；Ar为未取代的苯基或取代的苯基，取代基为卤素、C1-C6烷基、C1-C6烷氧基、取代氨基或三氟甲基；或Ar为取代或未取代的6元芳杂环之一，其中异杂环中含有两个氮原子；但不包括A1-A4式的化合物。本发明涉及新的化学化合物、其制备方法以及作为5-HT6受体拮抗剂的用途，同时调节细胞内钙离子的稳态。本发明涉及新的螺合的氮杂环-2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物，以及其制备方法、包括这些化合物作为活性物质的制药组合物，以及各种疾病的治疗和预防方法。
• SUSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
  申请人：Alla Chem, LLC

  公开号：US20130217703A1

  公开（公告）日：2013-08-22

  The present invention relates to a method of antagonizing a 5-HT 6 serotonin receptor and simultaneously regulating Ca +2 ion homeostasis in a cell, comprising administering to the cell a compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: R 1 is a C 1 -C 5 alkyl; R 2 i is independently hydrogen, halogen, a C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2, 3 or 4; Ar is an unsubstituted phenyl or a substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle with one or two nitrogen atoms in the heterocycle; and W is an ethylene group —CH 2 —CH 2 —, ethenyl group —CH═CH—, or ethynyl group —C≡C—. The invention also relates to new compounds selected from the group of compounds of the general formula 1, method for their preparation, pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease, or obesity in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1 according to claim 1 , or a pharmaceutically acceptable salt thereof.

  本发明涉及一种拮抗5-HT6 5-羟色胺受体和同时调节细胞内Ca+2离子稳态的方法，包括向细胞中投与式1的化合物或其药学上可接受的盐，其中：R1是C1-C5烷基；R2独立地是氢、卤素、C1-C3烷基、CF3、OCF3或OCH3；i为1、2、3或4；Ar是未取代的苯基或取代的苯基，其被卤素、C1-C6烷基、C1-C6烷氧基、取代的氨基团或三氟甲基取代；或Ar是带有一个或两个氮原子的取代或未取代的6元芳香杂环；W是乙烯基—CH2—CH2—、乙烯基—CH═CH—或乙炔基—C≡C—。本发明还涉及从式1的化合物组中选择的新化合物、其制备方法、制备药物组合物的方法以及治疗认知障碍或神经退行性疾病或肥胖症的方法，包括向需要治疗的受体中投与式1的化合物或其药学上可接受的盐的有效剂量。
• PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES
  申请人：HUNG David T.

  公开号：US20100216814A1

  公开（公告）日：2010-08-26

  This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文揭示了具有刚性基团的吡啶并[4,3-b]吲哚。在一种实施例中，化合物是具有不饱和碳氢基团的吡啶并[4,3-b]吲哚。在另一种实施例中，化合物是具有环烷基，环烯基或杂环基团的吡啶并[4,3-b]吲哚。还提供了包括这些化合物的制药组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍，精神障碍，神经递质介导的障碍和/或神经元障碍。
• SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF
  申请人：Alla Chem, LLC.

  公开号：EP2145887B1

  公开（公告）日：2016-04-27
• Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20100120792A1

  公开（公告）日：2010-05-13

  The invention relates to antagonists of serotonin 5-HT 6 receptors simultaneously regulating homeostasis of Ca +2 ions in cells, representing substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles of the general formula 1, pharmaceutically acceptable salts and/or hydrate thereof. In the general formula 1: R 1 represents amino group substituent selected from optionally substituted C 1 -C 5 alkyl; R 2 , is one or more substituents selected from hydrogen, halogen, C 1 -C 3 alkyl, CF 3 , OCF 3 ; Ar is phenyl optionally substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted amino group, or CF 3 ; or optionally substituted aromatic 6-membered heterocycle comprising 1-2 nitrogen atoms in the cycle; W represents ethylene group —CH 2 —CH 2 —, ethenyl group —CH═CH—, or ethynyl group —C≡C—. The invention also relates to the novel compounds selected from the compounds of the general formula 1, methods for their preparation, pharmaceutical compositions and methods of their use.